Oral corticosteroid therapy and present disease status in myasthenia gravis

Tomihiro Imai, Shigeaki Suzuki, Emiko Tsuda, Yuriko Nagane, Hiroyuki Murai, Masayuki Masuda, Shingo Konno, Yasushi Suzuki, Shunya Nakane, Kazuo Fujihara, Norihiro Suzuki, Kimiaki Utsugisawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG). Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status. Results: Achievement of MM or better at peak PSL dose (odds ratio 12.25, P<0.0001) and combined use of plasma exchange/plasmapheresis (PE/PP) and/or intravenous immunoglobulin (IVIg) (odds ratio 1.92, P=0.04) were associated positively, and total PSL dose during the past year (odds ratio 0.17, P=0.03) was associated negatively with present MM or better status. Conclusions: Higher PSL dose and longer PSL treatment do not ensure better outcome. In the absence of a good response, the PSL dose should be decreased by combining with modalities such as PE/PP or IVIg.

Original languageEnglish
Pages (from-to)692-696
Number of pages5
JournalMuscle and Nerve
Volume51
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Myasthenia Gravis
Prednisolone
Adrenal Cortex Hormones
Plasma Exchange
Plasmapheresis
Intravenous Immunoglobulins
Odds Ratio
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Imai, T., Suzuki, S., Tsuda, E., Nagane, Y., Murai, H., Masuda, M., ... Utsugisawa, K. (2015). Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle and Nerve, 51(5), 692-696. https://doi.org/10.1002/mus.24438

Oral corticosteroid therapy and present disease status in myasthenia gravis. / Imai, Tomihiro; Suzuki, Shigeaki; Tsuda, Emiko; Nagane, Yuriko; Murai, Hiroyuki; Masuda, Masayuki; Konno, Shingo; Suzuki, Yasushi; Nakane, Shunya; Fujihara, Kazuo; Suzuki, Norihiro; Utsugisawa, Kimiaki.

In: Muscle and Nerve, Vol. 51, No. 5, 01.05.2015, p. 692-696.

Research output: Contribution to journalArticle

Imai, T, Suzuki, S, Tsuda, E, Nagane, Y, Murai, H, Masuda, M, Konno, S, Suzuki, Y, Nakane, S, Fujihara, K, Suzuki, N & Utsugisawa, K 2015, 'Oral corticosteroid therapy and present disease status in myasthenia gravis', Muscle and Nerve, vol. 51, no. 5, pp. 692-696. https://doi.org/10.1002/mus.24438
Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, Masuda M et al. Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle and Nerve. 2015 May 1;51(5):692-696. https://doi.org/10.1002/mus.24438
Imai, Tomihiro ; Suzuki, Shigeaki ; Tsuda, Emiko ; Nagane, Yuriko ; Murai, Hiroyuki ; Masuda, Masayuki ; Konno, Shingo ; Suzuki, Yasushi ; Nakane, Shunya ; Fujihara, Kazuo ; Suzuki, Norihiro ; Utsugisawa, Kimiaki. / Oral corticosteroid therapy and present disease status in myasthenia gravis. In: Muscle and Nerve. 2015 ; Vol. 51, No. 5. pp. 692-696.
@article{fbd25324f751431ab80bc473552b21e7,
title = "Oral corticosteroid therapy and present disease status in myasthenia gravis",
abstract = "Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG). Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status. Results: Achievement of MM or better at peak PSL dose (odds ratio 12.25, P<0.0001) and combined use of plasma exchange/plasmapheresis (PE/PP) and/or intravenous immunoglobulin (IVIg) (odds ratio 1.92, P=0.04) were associated positively, and total PSL dose during the past year (odds ratio 0.17, P=0.03) was associated negatively with present MM or better status. Conclusions: Higher PSL dose and longer PSL treatment do not ensure better outcome. In the absence of a good response, the PSL dose should be decreased by combining with modalities such as PE/PP or IVIg.",
author = "Tomihiro Imai and Shigeaki Suzuki and Emiko Tsuda and Yuriko Nagane and Hiroyuki Murai and Masayuki Masuda and Shingo Konno and Yasushi Suzuki and Shunya Nakane and Kazuo Fujihara and Norihiro Suzuki and Kimiaki Utsugisawa",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/mus.24438",
language = "English",
volume = "51",
pages = "692--696",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Oral corticosteroid therapy and present disease status in myasthenia gravis

AU - Imai, Tomihiro

AU - Suzuki, Shigeaki

AU - Tsuda, Emiko

AU - Nagane, Yuriko

AU - Murai, Hiroyuki

AU - Masuda, Masayuki

AU - Konno, Shingo

AU - Suzuki, Yasushi

AU - Nakane, Shunya

AU - Fujihara, Kazuo

AU - Suzuki, Norihiro

AU - Utsugisawa, Kimiaki

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG). Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status. Results: Achievement of MM or better at peak PSL dose (odds ratio 12.25, P<0.0001) and combined use of plasma exchange/plasmapheresis (PE/PP) and/or intravenous immunoglobulin (IVIg) (odds ratio 1.92, P=0.04) were associated positively, and total PSL dose during the past year (odds ratio 0.17, P=0.03) was associated negatively with present MM or better status. Conclusions: Higher PSL dose and longer PSL treatment do not ensure better outcome. In the absence of a good response, the PSL dose should be decreased by combining with modalities such as PE/PP or IVIg.

AB - Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG). Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status. Results: Achievement of MM or better at peak PSL dose (odds ratio 12.25, P<0.0001) and combined use of plasma exchange/plasmapheresis (PE/PP) and/or intravenous immunoglobulin (IVIg) (odds ratio 1.92, P=0.04) were associated positively, and total PSL dose during the past year (odds ratio 0.17, P=0.03) was associated negatively with present MM or better status. Conclusions: Higher PSL dose and longer PSL treatment do not ensure better outcome. In the absence of a good response, the PSL dose should be decreased by combining with modalities such as PE/PP or IVIg.

UR - http://www.scopus.com/inward/record.url?scp=84928213168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928213168&partnerID=8YFLogxK

U2 - 10.1002/mus.24438

DO - 10.1002/mus.24438

M3 - Article

C2 - 25155615

AN - SCOPUS:84928213168

VL - 51

SP - 692

EP - 696

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 5

ER -